Paris-based Minos Biosciences SAS’ (www.minos.bio) mission is to improve the understanding and treatment of complex diseases such as cancer, infectious and autoimmune diseases. As AI-powered drug discovery and therapeutic innovation holds great promise, the company’s MinoSuite^TM integrated cell analysis platform creates unprecedented multimodal datasets that will offer direct, ground-truth labels for AI training, opening  up new possibilities ranging from fundamental research to drug development.

Despite significant advancements in patient care over the past 50 years, the prevalence of life-threatening diseases continues to rise. The pace of drug discovery is indeed steadily slowing down (Eroom’s law), which is largely attributed to the growing challenge of identifying new therapeutics that demonstrate both safety and efficacy in clinical trials. In this context, the advent of AI-driven target and/or drug discovery holds immense promise. However, the single greatest bottleneck limiting AI’s success is the availability of high-quality, large-scale training datasets as current analysis tools are reaching their limits: current discovery models are limited by fragmented, incomplete, and often biased datasets. The need for innovative, accurate, fast and cost-effective solutions addressing this gap is becoming increasingly pressing.

Minos Biosciences platform MinoSuite^TM,is designed to analyse cells and its interactions. It providesa comprehensive understanding of the molecular mechanisms underlying cell function and dynamics, in complex biological systems such as tumours and their microenvironment. The companby’s CAGE-tag^TM microfluidic technology combines image-based, dynamic functional monitoring and sequence-based molecular profiling of individual or multiple cells, to generate data of unprecedented depth and value.

“Minos’ USP lies in its unmatched ability to unravel biological complexity in all its dimensions with exceptional accuracy and depth, by linking a wide range of dynamic and functional characteristics of individual or interacting cells to their molecular profiles at cell resolution” says Pierre Le Ber, CEO of Minos Biosciences.

MinoSuite^TM generates rich, novel datasets primed for AI-driven analysis. In contrast, existing solutions offer only a limited, fragmented view of biological mechanisms. Leveraging its technology, Minos will deliver a range of high-impact assays,  providing cloud-based, AI-powered software for data analytics and visualisation.

Minos has established strong partnerships with top research institutions in France and is now kicking off its Early Access programme: its MinoSuite^TM Pioneer prototype will be deployed  to five KOLs in Europe and in the USA, starting with Pasteur Institute in the next few weeks. At the same time, Minos is seeking a Series A fundraise to prepare for full commercial launch of our instrument, software and consumables (microfluidic system and reagent kits) anticipated in early 2027.

The company will not participate in the SLAS Ingnite and the New Product Award.